Grande Ospedale Metropolitano Bianchi Melacrino Morelli
- Address
- lock Available on a paid plan
Grande Ospedale Metropolitano Bianchi Melacrino Morelli - Hematologic Malignancies Research Center
The Grande Ospedale Metropolitano Bianchi Melacrino Morelli stands as a leading center for hematologic malignancy research, with extensive expertise in treating complex blood cancers and bone marrow disorders. The institution specializes in minimal residual disease (MRD) monitoring and targeted therapy approaches, conducting cutting-edge clinical trials that advance treatment paradigms for patients with both acute and chronic hematologic conditions.
- Acute and chronic leukemias, including AML, Philadelphia chromosome-positive ALL, chronic lymphocytic leukemia, chronic myeloid leukemia, and hairy cell leukemia
- Lymphoproliferative disorders, including mantle cell lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, and splenic marginal zone lymphoma
- Myelodysplastic syndromes and myeloproliferative neoplasms, including myelofibrosis and polycythemia vera
- Multiple myeloma management and hematopoietic stem cell transplantation, including graft-versus-host disease prevention and treatment
The center demonstrates particular strength in evaluating novel therapeutic combinations, including BTK inhibitors, BCL-2 inhibitors, tyrosine kinase inhibitors, and immunotherapies such as monoclonal antibodies and CAR-T cell therapy. Research focuses extensively on precision medicine approaches, incorporating genetic profiling and MRD assessment to guide treatment decisions. The institution maintains comprehensive programs in both autologous and allogeneic stem cell transplantation, with significant expertise in transplant-related complications and maintenance therapy strategies for achieving deep, durable remissions across the spectrum of hematologic malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 9 therapeutic areas and 15 of 137 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 125 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Grande Ospedale Metropolitano Bianchi Melacrino Morelli
lock Showing 1 of 65 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | Celgene Corp. | Phase IV | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 137 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cytarabine | 9 | Unknown | 2018-07-15 | 2024-12-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.